Covered recipient · General Payments record
ALYSON PENSTEIN
General Payments · PY2018–2024
$478.18
- Reported across 19 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $210.23 | 9 |
| Education | $99.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $212.00 | 6 |
| REVANCE THERAPEUTICS, INC. | $57.83 | 2 |
| Amgen Inc. | $24.26 | 1 |
| Incyte Corporation | $16.13 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2018201920222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $24.26 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117351127 | CMS |
| Incyte Corporation | $16.13 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141302737 | CMS |
| Janssen Biotech, Inc. | $30.18 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078449055 | CMS |
| Janssen Biotech, Inc. | $99.99 | 05/22/2024 | Education | Undisputed | 01/23/2026 | 1078439948 | CMS |
| Janssen Biotech, Inc. | $5.44 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078458065 | CMS |
| Janssen Biotech, Inc. | $24.45 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078449742 | CMS |
| Janssen Biotech, Inc. | $28.35 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078452679 | CMS |
| Janssen Biotech, Inc. | $23.59 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078442516 | CMS |
| REVANCE THERAPEUTICS, INC. | $27.86 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147926613 | CMS |
| REVANCE THERAPEUTICS, INC. | $29.97 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147926615 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.